Companhia de Saneamento B... (SBS)

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Str...

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI C...

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for c...

SABESP is just beginning to unlock the benefits of privatization, with a bold R$70 billion investment plan through 2030 aimed at full sanitation coverage. Despite macro headwinds in Brazil, SBS ADRs h...

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and mi...

Invest in companies like ALLT, SBS, LNN, EQBK and GFF to make the most of higher efficiency levels.

In this period of extreme market turbulence, large-cap value stocks are outperforming large-cap growth stocks by nearly 8% YTD. This is a seismic shift in the style regime, as mega-cap growth has typi...

Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shor...

I am upgrading my recommendation on Sabesp shares from hold to buy due to strong 4Q24 results, showing revenue and profit growth. Despite a lower EBIT due to redundancy provisions, Sabesp's operationa...

Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:SBS ) Q4 2024 Earnings Conference Call March 25, 2025 12:00 PM ET Company Participants Thiago Levy - Investor Relations Director Da...